MK-677 (Ibutamoren) + Thymosin Alpha-1 Stack: Evidence, Mechanism Overlap, and Protocol

Is there any evidence for this stack?

The two compounds have been studied in different settings: MK-677 in growth hormone deficiency, healthy older adults, hip-fracture recovery and Alzheimer's disease, and thymosin alpha-1 in chronic hepatitis B, sepsis, and as a vaccine adjuvant in some countries [10][11][12][13][6]. FDA's review of MK-677 reports no formal drug-interaction studies [1].

What MK-677 does

MK-677 (ibutamoren mesylate) is an oral, non-peptide small molecule that stimulates growth hormone release through the ghrelin (growth hormone secretagogue) receptor, raising pulsatile GH and IGF-1; a single dose is reported to stay active for about 24 hours [1]. Merck first synthesized it in 1995 and discontinued development in 1999. It has no USP or National Formulary monograph and is not a component of any FDA-approved drug, and despite the way it is sold it is not a SARM [1].

Ibutamoren is also under study under the name LUM-201 for pediatric growth hormone deficiency. In a 6-month randomized placebo-controlled trial of 68 prepubertal children, FDA's review says it was generally well tolerated, with increased appetite the most common drug-related event, reported 2.5 to 3 times more often than with placebo [10][1].

What thymosin alpha-1 does

Thymosin alpha-1 (thymalfasin) is a 28-amino-acid peptide with an acetylated N-terminal end, originally isolated from thymosin fraction 5, a thymus extract; thymalfasin is the synthetic version with the same sequence [6]. It is described as an immune modulator that augments T-cell function [2], and it signals through Toll-like receptors on myeloid and plasmacytoid dendritic cells [3]. After subcutaneous injection in healthy volunteers it peaks at about 0.7 to 2 hours, has a half-life of about 1.8 to 2.6 hours, and did not accumulate over five daily doses [6].

Zadaxin is the brand of the finished 1.6 mg injection sold outside the US, and it is not interchangeable with bulk thymosin alpha-1 powder [6].

Do the mechanisms overlap?

The available descriptions of each compound point to different primary targets. MK-677's documented action is endocrine: ghrelin-receptor stimulation, GH release and an IGF-1 rise [1]. Thymosin alpha-1's documented action is immunological: T-cell function and dendritic-cell signaling through Toll-like receptors [2][3].

The trial programs reflect that split. The MK-677 studies measured body composition, physical function, bone density, glucose and Alzheimer's progression [11][12][13][14]. The thymosin alpha-1 studies measured hepatitis B virology, mortality, and immune markers such as monocyte HLA-DR in sepsis [15][16][17].

What the MK-677 trials found

A 12-month comparison in 65 healthy adults aged 60 to 81 given 25 mg daily raised fat-free mass by 1.1 kg against a 0.5 kg fall on placebo, and body weight by 2.7 kg against 0.8 kg. Fasting glucose rose about 5 mg/dL (P=0.015) and insulin sensitivity fell. Strength and function did not improve. The most frequent side effects were increased appetite, transient mild leg edema and muscle pain [11].

A hip-fracture trial of 123 patients was stopped early for a congestive heart failure signal. Per FDA's summary, heart failure occurred in 4 patients (6.5%) on MK-677 and 1 (1.7%) on placebo [1][5]. Systolic blood pressure rose 11.9 to 16.4 mmHg, against 2.3 to -2.3 on placebo, and IGF-1 rose 51.4 ng/mL more than placebo [5][1].

A second hip-fracture trial of 161 patients aged 65 and older ran 6 months: IGF-1 rose 84% against 17% on placebo, with no significant functional benefit, and per FDA's summary glucose rose 8.0 mg/dL against a 1.6 mg/dL fall, HbA1c rose 0.7% against 0.3%, and thrombosis occurred in 4 patients against none [12][1].

In 563 patients with mild to moderate Alzheimer's disease treated for 12 months, IGF-1 rose 72.9% with no effect on disease progression. Drug-related adverse events were 35.5% against 23.9% on placebo, and blood glucose increases occurred in 15.4% against 4.6% [13].

In 292 postmenopausal women with osteoporosis, adding MK-677 to alendronate raised femoral neck bone density 4.2% against 2.5% with alendronate alone, with no extra gain at the spine, total hip or total body [14].

Across these trials MK-677 raised IGF-1, but it did not improve strength or function in healthy older adults, did not produce a significant functional benefit after hip fracture, and did not slow Alzheimer's disease progression [11][12][13].

What the thymosin alpha-1 trials found

A 2026 Cochrane review pooled 10 randomized trials with 1349 adults with chronic hepatitis B, published between 1991 and 2018. It found possible lower all-cause mortality (risk ratio 0.53, 95% CI 0.29 to 0.96; 3 trials, 907 people) at very low certainty, little to no effect on quality of life or liver histology, and reviewers who said they were not sure thymosin alpha-1 helps [15].

In 98 adults with HBeAg-positive hepatitis B, adding thymosin alpha-1 to interferon for 24 weeks produced HBeAg loss at 72 weeks of 45.8% against 28.0% (difference 17.8%, 95% CI -1.2 to 35.3, P=0.067), which did not reach statistical significance [16]. A 1991 pilot of only 12 people found HBV DNA cleared in 6 of 7 treated patients against 1 of 5 on placebo [18]. In severe sepsis, a 361-patient trial reported 28-day mortality of 26.0% against 35.0% (relative risk 0.74, 95% CI 0.54 to 1.02) [17].

Doses that were tested

There is no US-approved dose of either. MK-677 trials used fixed oral doses of 2 mg to 50 mg per day, most often 25 mg once daily in adults, or 0.2 to 0.8 mg/kg/day in children, for up to 2 years [1]. The Italian Zadaxin label uses 1.6 mg subcutaneously or intramuscularly twice weekly for 4 weeks starting at the first influenza vaccination, repeated from week 8 to week 12 at the second [6]. A hepatitis B trial added thymosin alpha-1 to interferon three times weekly for 24 weeks [16].

What to watch for

FDA's concern about MK-677 is class-wide. By raising GH and IGF-1 it may carry the risks listed on approved growth hormone labels: increased risk of neoplasm, glucose intolerance and diabetes, intracranial hypertension, fluid retention, hypoadrenalism, hypothyroidism, pancreatitis, and in children slipped capital femoral epiphysis and scoliosis progression [1]. FDA's stated reason for placing it among bulk substances with significant safety risks is the potential for congestive heart failure in certain patients [4]. Trials also reported increased appetite, leg edema, muscle pain, raised cortisol and reversible liver enzyme rises [11][1]. There are no long-term safety data in the older adults it is marketed to [1].

For thymosin alpha-1, FDA's search of its adverse-event database on April 22, 2024 found zero reports [6]. Authors tied to the manufacturer report more than 4,400 people enrolled in trials and more than 17 million doses given after marketing, with adverse experiences infrequent and mild; that is company-linked data [6]. The 2026 Cochrane review found thymosin alpha-1 may have caused fewer serious adverse events than comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1056 people; low-certainty evidence) [15]. The Italian label says it is not for children, is contraindicated in pregnancy and breastfeeding, and calls for caution in people with allergies or autoimmune disease and with other immune-modulating drugs [6]. FDA's compounding review listed a significant risk of immunogenicity for certain routes of administration, plus peptide-impurity and characterization problems [4].

Regulatory status

In a December 12, 2025 warning letter, FDA said ibutamoren is excluded from the dietary supplement definition and that products marketed with drug claims for it are unapproved new drugs [8]. It sits in FDA's category 2 for both state-licensed pharmacies (added September 29, 2023) and outsourcing facilities (December 29, 2022); FDA's category 1 policy of generally not acting against compounders does not apply to it [4][19][20]. On October 29, 2024 the Pharmacy Compounding Advisory Committee voted 1 yes and 13 no against adding it to the bulks list, citing fluid retention, congestive heart failure and hyperglycemia [21]. It is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [22][23]. WADA names ibutamoren in S2.2.4 and prohibits it at all times, in and out of competition [9][24].

Thymosin alpha-1 is not FDA-approved; it holds four US orphan drug designations, which are a separate process from approval [6]. FDA lists national authorizations in Italy, as an adjuvant to influenza vaccination in immunocompromised people, in India for chronic hepatitis B in adults with compensated liver disease and virus replication, and in Hong Kong, while the European Medicines Agency has granted only an orphan designation for hepatocellular carcinoma [6]. Two older reviews by authors tied to the Zadaxin developer claim approval in more than 35 countries (2009) and more than 30 (2007) [25][26]. On FDA's compounding lists it appears in the nominated-but-withdrawn table, having previously been in category 2, with FDA's stated immunogenicity concerns still posted; it is in none of the three categories for state-licensed pharmacies and in category 3 for outsourcing facilities [4][19][20]. The advisory committee voted 4 yes and 17 no on December 4, 2024 [7]. It is not named on WADA's 2026 or 2027 lists, though thymosin beta-4 and TB-500 are, and those are different peptides [9][24].